First-line Chemotherapy in Epithelial Ovarian Cancer
First-line Chemotherapy in Epithelial Ovarian Cancer
复制标题
DOI：
10.1097/grf.0b013e31824b45da
复制
发表时间：
2012-03-01
影响因子：
1.5
通讯作者：
Bookman, Michael A.
中科院分区：
文献类型：
--
作者：
Bookman, Michael A.
尽管进行了有效的细胞减灭术和初级化疗，晚期上皮性卵巢癌仍然是一种高度致命的恶性肿瘤。第三阶段研究评估了多种药物组合、剂量密度每周计划、腹膜内给药、新辅助化疗、维持治疗和血管生成靶向。在中位无进展或总体生存率方面取得了增量增长，但对总体死亡率没有影响。数据支持在适当的患者中采用顺铂、每周剂量密集的紫杉醇或间歇性细胞减少的新辅助化疗。使用抗血管生成药物已经出现了令人鼓舞的数据，但存在关于最佳时机和患者选择的问题。不支持使用3种药物组合或维持化疗。
Advanced-stage epithelial ovarian cancer remains a highly lethal malignancy, despite effective cytoreductive surgery and primary chemotherapy. Phase III studies have evaluated multidrug combinations, dose-dense weekly scheduling, intraperitoneal delivery, neoadjuvant chemotherapy, maintenance therapy, and targeting of angiogenesis. Incremental gains in median progression-free or overall survival have been achieved, but without an impact on overall mortality. Data support intraperitoneal cisplatin, dose-dense weekly paclitaxel, or neoadjuvant chemotherapy with interval cytoreduction in appropriate patients. Encouraging data have emerged using anti-angiogenic agents, but with questions regarding optimal timing and patient selection. The use of 3-drug combinations or maintenance chemotherapy is not supported.